Oral corticosteroid dosage reduction sustained in open-label extension study of dupilumab
Your search for oral corticosteroids returned 16 results
TRAVERSE trial findings on the efficacy, safety, and OCS-sparring effect of dupilumab for severe OCS-dependent asthma were presented at ATS 2022.
Post hoc analysis of the VENTURE/TRAVERSE trials assessed dupilumab efficacy in patients with severe asthma requiring varying levels of oral corticosteroids at baseline.
Investigators explored the value of treating patients with bronchiolitis in primary Sjogren’s Syndrome using inhaled corticosteroids and long-acting beta agonists.
The researchers conducted a retrospective cohort study using claims data from the Optum Research Database for 538 patients at least 6 years of age who initiated mepolizumab treatment for asthma between January 2016 and December 2019.
Patients with flares more likely to have inpatient, emergency department visits
Efzofitimod is a potential first-in-class selective modulator of neuropilin-2 that is designed to downregulate innate and adaptive immune responses in inflammatory disease states.
Dupixent single-dose prefilled pens feature a hidden needle and single-press auto-injection.
Investigators assessed the annualized asthma exacerbation rate (AAER) and the annualized rate of asthma exacerbations requiring hospitalization over 52 weeks.
A post hoc analysis of the NAVIGATOR trial assessed the effectiveness of tezepelumab in patients with severe asthma who used additional controllers medications.